Location of primary tumor and benefit from anti-epidermal growth factorreceptor monoclonalantibodies in patients with RAS and BRAF wild-typemetastatic colorectal cancer

Roberto Moretto, Chiara Cremolini, Daniele Rossini, Filippo Pietrantonio, Francesca Battaglin, Alessi Amennitto, Francesca Bergamo, Fotios Loupakis, Federica Marmorino, Rosa Berenato, Valentina Angelamarsico, Marta Caporale, Carlotta Antoniotti, Gianluca Masi, Lisa Salvatore, Beatrice Borelli, Gabriella Fontanini, Sara Lonardi, Filippo De Braud, Alfredo Falconea

Research output: Contribution to journalArticle

Abstract

Introduction. Right- and left-sided colorectal cancers (CRCs) differ in clinical and molecular characteristics. Some retrospective analyses suggested that patients with right-sided tumors derive less benefit from anti-epidermal growth factor receptor (EGFR) antibodies; however, molecular selection in those studies was not extensive. Patients and Methods. Patients with RAS and BRAF wild-type metastatic CRC (mCRC) who were treated with single-agent anti-EGFRs or with cetuximab-irinotecan (if refractory to previous irinotecan) were included in the study. Differences in outcome between patients with right- and left-sided tumors were investigated. Results. Of 75 patients, 14 and 61 had right- and left-sided tumors, respectively. None of the right-sided tumors responded according to RECIST, compared with 24 left-sided tumors (overall response rate: 0% vs. 41%; p 5 .0032), and only 2 patients with right-sided tumors (15%) versus 47 patients with left-sided tumors (80%) achieved disease control (p, .0001). The median duration of progression-free survival was 2.3 and 6.6 months in patients with right-sided and left-sided tumors, respectively (hazard ratio: 3.97;95%confidence interval: 2.09–7.53; p,.0001). Conclusion. Patients with right-sided RAS and BRAF wild-type mCRC seemed to derive no benefit from single-agent anti- EGFRs.

Original languageEnglish
Pages (from-to)988-994
Number of pages7
JournalOncologist
Volume21
Issue number8
DOIs
Publication statusPublished - Aug 1 2016

Keywords

  • Anti-EGFR monoclonal antibodies
  • Left-sided tumor
  • Metastatic colorectal cancer
  • Right-sided tumor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Location of primary tumor and benefit from anti-epidermal growth factorreceptor monoclonalantibodies in patients with RAS and BRAF wild-typemetastatic colorectal cancer'. Together they form a unique fingerprint.

  • Cite this

    Moretto, R., Cremolini, C., Rossini, D., Pietrantonio, F., Battaglin, F., Amennitto, A., Bergamo, F., Loupakis, F., Marmorino, F., Berenato, R., Angelamarsico, V., Caporale, M., Antoniotti, C., Masi, G., Salvatore, L., Borelli, B., Fontanini, G., Lonardi, S., De Braud, F., & Falconea, A. (2016). Location of primary tumor and benefit from anti-epidermal growth factorreceptor monoclonalantibodies in patients with RAS and BRAF wild-typemetastatic colorectal cancer. Oncologist, 21(8), 988-994. https://doi.org/10.1634/theoncologist.2016-0084